The General Public’s Willingness to Pay for Tax Increases to Support Unrestricted Access to an Alzheimer’s Disease Medication

[1]  W. Thies,et al.  2013 Alzheimer's disease facts and figures , 2013, Alzheimer's & Dementia.

[2]  G. Léger,et al.  Pharmacological Treatment of Alzheimer Disease , 2011, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[3]  P. Raina,et al.  Support for a tax increase to provide unrestricted access to an Alzheimer's disease medication: a survey of the general public in Canada , 2009, BMC health services research.

[4]  Linus Jönsson,et al.  Willingness‐to‐pay for reductions in care need: estimating the value of informal care in Alzheimer's disease , 2009, International journal of geriatric psychiatry.

[5]  P. Raina,et al.  The Canadian Longitudinal Study on Aging (CLSA)* , 2009, Canadian Journal on Aging / La Revue canadienne du vieillissement.

[6]  Stephen Abela,et al.  Dementia in Malta: Experiences of dementia patients and their caregivers , 2009, Alzheimer's & Dementia.

[7]  Steve Iliffe,et al.  Alzheimer’s disease , 2009, BMJ : British Medical Journal.

[8]  M. Oremus,et al.  A systematic review of the use of contingent valuation in Alzheimer's disease research , 2008 .

[9]  C. León,et al.  Willingness to pay for alternative policies for patients with Alzheimer’s Disease , 2008, Health Economics, Policy and Law.

[10]  P. Raina,et al.  Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline , 2008, Annals of Internal Medicine.

[11]  P. Zweifel,et al.  Willingness-to-pay Against Dementia: Effects of Altruism Between Patients and Their Spouse Caregivers , 2004 .

[12]  D. Bennett,et al.  Alzheimer disease in the US population: prevalence estimates using the 2000 census. , 2003, Archives of neurology.

[13]  M. König,et al.  Caring for relatives with dementia: willingness-to-pay for a reduction in caregiver’s burden , 2002, Expert review of pharmacoeconomics & outcomes research.

[14]  H. Telser,et al.  The Contingency of Contingent Valuation How Much Are People Willing to Pay against Alzheimer's Disease? , 2002, International Journal of Health Care Finance and Economics.

[15]  J. Aharon,et al.  Family Caregivers’ Willingness to Pay for Drugs Indicated for the Treatment of Alzheimer’s Disease , 2002 .

[16]  T Ostbye,et al.  A reevaluation of the duration of survival after the onset of dementia. , 2001, The New England journal of medicine.

[17]  W. Shyu,et al.  Willingness of families caring for victims of dementia to pay for nursing home care: results of a pilot study in Taiwan. , 1998, Journal of management in medicine.

[18]  Truls Østbye,et al.  Net economic costs of dementia in Canada. , 1994, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[19]  Robin Eastwood,et al.  Canadian study of health and aging , 1992 .

[20]  M. Gatz,et al.  The Alzheimer's disease knowledge test. , 1988, The Gerontologist.

[21]  S. Zarit,et al.  The Hidden Victims of Alzheimer's Disease: Families Under Stress , 1985 .

[22]  A. Bayoumi.  The Measurement of Contingent Valuation for Health Economics , 2012, PharmacoEconomics.

[23]  M. Rafii.  The pulse of drug development for Alzheimer's disease. , 2010, Reviews on recent clinical trials.

[24]  M. Kenward,et al.  An Introduction to the Bootstrap , 2007 .

[25]  N. Herrmann,et al.  The Cost-Benefit of Cholinesterase Inhibitors in Mild to Moderate Dementia , 2003, CNS drugs.

[26]  A. Williams.  EuroQol : a new facility for the measurement of health-related quality of life , 1990 .